Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin

Abstract

AimsAcute myeloblastic leukemia (AML) is the most common type of acute leukemia in adults. Despite numerous treatment strategies including chemotherapy and radiotherapy, a large number of patients do not respond to treatment and experience relapse. The main problem of these patients is the development of resistance to anti-cancer drugs. Therefore, any endeavor to reduce drug resistance in these patients is of high priority. In general, several mechanisms such as changes in drug metabolic pathways, drug inactivation, drug target alterations and reduced drug accumulation in the cells contribute to drug resistance of cancer cells. In this context, evidence suggests that exosomes could reduce drug resistance by removing drugs from their parent cells. In the present study, we aimed to investigate the effects of exosome release inhibition on the resistance of U937 cells to PEGylated liposomal doxorubicin (PLD).Main MethodsIn order to find a suitable ABCG2 (ATP-binding cassette sub-family G member 2) transporter substrate, virtual screening was performed among a list of drugs used in leukemia and PLD was selected. U937 cells were treated with PLD with/without co-treatment with the exosome release inhibitor, GW4869. Released exosomes within different study groups were isolated and characterized to determine the differences between groups. Doxorubicin presence in the isolated exosomes was also measured by high performance liquid chromatography (HPLC) to confirm drug export through the exosomes. Finally, the effect of exosome inhibition on the cytotoxicity of PLD on U937 cells was determined using different cytotoxicity assays including the standard lactate dehydrogenase (LDH) release assay and the flow cytometric analysis of apoptotic and non-apoptotic cell death.Key FindingsGW4869 treatment caused a significant decrease in the exosome release of U937 cells compared to the untreated cells, as evidenced by the reduction of the protein content of the isolated exosomes (P<0.05). Co-treatment with GW4869 significantly increased cytotoxic cell death in the groups treated with 0.5 and 1 µM PLD, compared to the same groups without GW4869 co-treatment (P<0.05). Interestingly, co-treatment with GW4896 and 0.5 µM PLD was enough to induce the same cytotoxic effect as that of the sole 1 µM PLD group.SignificanceOur findings showed that U937 cells increase their resistance against the cytotoxic effects of PLD through the exosome-mediated expelling of the drug. Inhibition of exosome release could prevent PLD efflux and consequently increase the vulnerability of the U937 cells to the cytotoxic effects of PLD. Our results along with prior studies indicate that the integration of exosome release inhibitors into the common PLD-containing chemotherapy regimens could significantly lower the required concentrations of the drug and consequently reduce its associated side effects. Further studies are warranted to identify clinically safe inhibitors and investigate their clinical efficacy.

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment

“…This suggests that the small EV population is likely to be responsible for mediating the response of cells to the treatment. To our knowledge, this has not been previously shown in PDAC but is in keeping with other literature that shows sensitisation to chemotherapies in other cancers, for example, to doxorubicin in acute myeloid leukaemia [27].…”

Emergence of Edible Plant-Derived Nanovesicles as Functional Food Components and Nanocarriers for Therapeutics Delivery: Potentials in Human Health and Disease

“…Last but not least, an investigation on the safety of PDNVs needs to be undertaken. Although no study has alerted or measured the presence of toxic chemicals such as herbicides and pesticides in the isolated PDNVs, given that mammalian exosomes release harmful or unwanted substances as a self-survival mechanism [ 113 , 114 ], PDNVs may contain a concentrated form of poisonous substances [ 115 ]. Therefore, rigorous analysis on the PDNVs’ cargo need to be carried out.…”

Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment

“…Some miRNAs can directly target drug-efflux mRNAs. For example, TDEVs secreted by U937 cells promote efflux of the drug PEGylated liposomal doxorubicin (PLD), thereby increasing its resistance to the toxic effects of PLD cells 54 . TDEVs promotes tumor drug resistance through a variety of mechanisms, which limits the treatment of cancer 55 .…”